Continuous Flow — An Emerging Alternative

By Dr Sripathy Venkatraman, Head Of R&D Operations, Curia

Pharmaceutical companies have traditionally been risk-averse, adopting safe and well-established processes due to conservative regulatory agencies. However, this is changing.

The growing complexity of drug molecules and the need for newer, harsher reaction conditions have positioned continuous flow chemistry and processing as viable alternatives. Over the last decade, commercial continuous flow units have been developed for both research and large-scale production, with GMP-compliant units capable of rapid scale-up increasing interest and accessibility.

Download our white paper to gain insights on the transition from batch to continuous flow, the advantages of continuous flow chemistry, regulatory compliance and quality by design (QbD) principles, and case studies showcasing practical implementation of continuous flow processes.